Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
Healthcare
$251.41 -1.11%
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
52W Low $121.05High $205.97
Volume 1.14M
Average 1.17M
News
For Biogen Inc., read summarized stories built from several publishers and recent headlines with links to the original coverage.
Stories
All market newsNo stories for BIIB yet. A story appears once at least three publishers cover the same event.
More headlines
Recent coverage that has not been summarized. Links open the publisher's site.
- New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
PRNewsWire
- Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
MarketBeat
- Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Reuters
- Biogen: 3 Key Takeaways for Long-Term Investors
The Motley Fool
- Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease
GlobeNewsWire
- Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha
- The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of publicly-traded Biogen Inc. common stock– BIIB
GlobeNewsWire
- New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
PRNewsWire
Continue the stock analysis
Jump to another research area for this company.